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i.org/1clinical impact on mortality is unclear. The aim of our study was to evaluate the prognostic
value of N-terminal pro-brain natriuretic peptide (NT-proBNP) in the prediction of
all-cause mortality in adults with different CHD. In this prospective longitudinal mortality
study, we evaluated NT-proBNP in 1,242 blood samples from 646 outpatient adults with
stable CHD (mean age 35 – 12 years; 345 women). Patients were followed up for 6 – 3 (1 to
10) years. The mortality rate was 5% (35 patients, mean age 40 – 14 years, 17 women).
Median NT-proBNP (pg/ml) was 220 in the whole cohort, 203 in survivors, and 1,548 in
deceased patients. The best discrimination value for mortality prediction was 630 pg/ml
with 74% sensitivity and 84% speciﬁcity. During the follow-up, the survival rate was 65%
for those with median NT-proBNP ‡630 pg/ml and 94% for NT-proBNP <630 pg/ml;
p <0.0001. There was only 1% mortality among 388 patients with at least 1 NT-proBNP
value £220 pg/ml compared with 41% mortality among 54 patients with at least
1 NT-proBNP value >1,548 pg/ml. Even the ﬁrst (baseline) measurements of NT-proBNP
were strongly associated with a high risk of death (log10 NT-proBNP had hazard ratio
7, p <0.0001). In conclusion, NT-proBNP assessment is a useful and simple tool for the
prediction of mortality in long-term follow-up of adults with CHD.  2015 The Authors.
Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/). (Am J Cardiol 2015;116:1425e1430)Natriuretic peptides are powerful independent markers of
prognosis in patients with symptomatic or asymptomatic heart
failure, coronary artery disease, pulmonary hypertension,
acquired valve disease, and general population but not in the
healthy population without cardiovascular risk factors.1e8
Patients with low level of N-terminal pro-brain natriuretic
peptide (NT-proBNP) have excellent prognosis irrespective of
echocardiographic ﬁndings.2,9 For patients with advanced
chronic heart failure, natriuretic peptides have been accepted
as a gold standard in predicting mortality.8,10,11 It is less clear
which levels of NT-proBNP may be considered normal and
which have negative prognostic impact in the population of
adults with congenital heart disease (ACHD).12,13 The
average (reference) values of NT-proBNP for the main
congenital heart diagnoses in adulthood were proposed by
2 larger studies.14,15 The usefulness of natriuretic peptides forf Cardiac Surgery, Hospital Na Homolce, Prague, Czech
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0.1016/j.amjcard.2015.07.070mortality prediction in ACHD has been studied in smaller
studies for speciﬁc complex lesions.16e19 The aim of our
study was to assess the prognostic value of NT-proBNP for
mortality prediction in a large cohort of ACHD during long-
term follow-up. To the best of our knowledge, this is the
largest study in ACHD evaluating NT-proBNP in mortality
prediction.
Methods
During the period 2003 to 2013, we measured
NT-proBNP prospectively in 646 consecutive adults with
different congenital heart lesions referred to our center. All
blood samples were obtained during the planned outpatient
visit. Only adult patients in stable state were included in this
study; those referred to hospitalization with manifest heart
failure or arrhythmia during the ﬁrst visit were excluded.
Patients with renal failure and creatinine level >160 mmol/l
were not included in the study.
The ﬁrst NT-proBNP measurement was considered
baseline. Repeated NT-proBNP assessments were per-
formed during the controls in our center. All patients were
regularly followed up either in our tertiary referral center for
ACHD or by local cardiologists. The mortality rate of our
patients was conﬁrmed by the confrontation of all patients
with the National Mortality Register. If the death happened
outside the hospital, we tried to ﬁnd out the cause of the
death by a telephone call to the family, local cardiologist, or
general practitioner.
Blood samples for NT-proBNP were withdrawn during the
outpatient visit in the morning in a sitting position at rest from
a peripheral vein together with blood samples for routinewww.ajconline.org
Table 1
Characteristics of the 646 adult patients with congenital heart disease (CHD)
Diagnosis Pts N of NT-proBNP
samples
Pts after repair
N (%)
Pts without
radical repair
N (%)
N of deaths/
deaths after
radical repair
Rate of deaths
within
dg group
Rate of deaths
within all
35 deaths
Pulmonary atresia 24 46 18 (75 %) 6 (25 %) 2/2 8 % 6 %
Congenitally corrected
transposition of the great arteries
22 43 9 (41 %) 13 (59 %) 0 0 0
Ventricular septal defect* 34 57 22 (65 %) 12 (35 %) 0 0 0
Fontan correction† (27) (57) (27) (100 %) 0 (0) 0 0 0
Single ventricle† incl. Tricuspid atresia 48 92 31 (65 %) 17 (35 %) 5/1 10 % 14 %
Eisenmenger syndrome or severe
pulmonary hypertension*
51 106 15 (29 %) 36 (71 %) 6/2 12 % 17 %
Coarctation of the aorta 25 38 22 (88 %) 3 (12 %) 0 0 0
Ebstein anomaly 49 120 31 (63 %) 18 (37 %) 6/3 12 % 17 %
Transposition of the great arteries 86 185 84 (98 %) 2 (2 %) 9/8 10 % 26 %
Tetralogy of Fallot 96 188 92 (96 %) 4 (4 %) 2/1 2 % 6 %
Atrial septal defect 90 142 57 (63 %) 33 (37 %) 1/1 1 % 2.8 %
Atrio-ventricular septal defect 29 50 25 (86 %) 4 (14 %) 3/3 10 % 8.6 %
Truncus arteriosus 3 3 3 (100 %) 0 0 0 0
Pulmonary stenosis 29 44 23 (79 %) 6 (21 %) 1/1 3% 2.8 %
Congenital aortic valve disease 56 118 16 (29 %) 40 (71 %) 0 0 0
Other 4 10 3 (75 %) 1 (25 %) 0 0 0
Together 646 1242 451 (70 %) 195 (30 %) 35/22 100 %
dg ¼ diagnosis.
* Patients with ventricular septal defect, atrial septal defect, or any other lesion with severe pulmonary hypertension are included only in the Eisenmenger group.
† All patients with Fontan correction are included also in the single ventricle group.
1426 The American Journal of Cardiology (www.ajconline.org)biochemistry and blood count evaluation. Serum samples
were analyzed immediately after the transport to the labora-
tory. Serum levels of NT-proBNP were measured using
commercially available electrochemiluminescence sandwich
immunoassay (Elecsys 2010; Roche, Mannheim, Germany).
The KaplaneMeier analysis with the log-rank Man-
teleCox test was used for evaluation of survival curves.
The negative and positive predictive values, sensitivity,
speciﬁcity, and area under the curve (AUC) were assessed
for different NT-proBNP cut-off values. The effect of log10
NT-proBNP on survival was assessed by Cox proportional
hazard ratio (HR) analysis and resulting signiﬁcance, HR,
and conﬁdence intervals of HR were reported; fulﬁllment of
Cox proportional hazards assumptions were tested using
R function cox.zph. The ManneWhitney U test was used to
compare the differences in NT-proBNP values between
survivors and deceased patients. The value of p <0.05 was
considered statistically signiﬁcant. The GraphPad Prism
version 6.0 (San Diego, California) and R software version
3.1.2 were used to perform the statistical analysis.
The study was approved by the local ethics committee.
All patients were informed about the purpose of
NT-proBNP assessment and gave their informed consent
with the NT-proBNP analysis.
Results
The mean follow-up was 6  3 (1 to 10) years in the
period between 2003 and 2013. The mean age of our
patients was 35  12 years (18 to 79 years), there were 301
men and 345 women. The overview of different CHD
diagnoses, number of patients and blood samples, history of
repair, and deaths are summarized in Table 1.Most patients (70%) had a history of radical repair of
their CHD, mostly in childhood (58%), less frequently in
adulthood (12%); the remaining 30% did not have any
operation or had only a palliative shunt. The group with
unrepaired CHD comprised patients with severe inoperable
lesions and patients with mild lesions not indicated for
surgery. Most patients (81%) were only mildly symptomatic
(New York Heart Association [NYHA] classes I to II) and
19% had NYHA classes III to IV. Cyanosis with oxygen
saturation 90% was present in 7% of patients without
radical correction (Eisenmenger syndrome, Ebstein anom-
aly, functionally single ventricle or palliated tetralogy of
Fallot). All our patients had normal creatinine levels except
one with mild renal failure and serum creatinine 150 mmol/l.
Repeated NT-proBNP assessment was performed in 46% of
the whole cohort (295 patients).
Thirty-ﬁve patients (5%) died during follow-up at the
mean age of 40  14 years, 17 were women. The most
frequent diagnoses in the deceased group were trans-
position of the great arteries after Mustard or Senning
correction or without correction (26% of deaths), Ebstein
anomaly (17%), Eisenmenger syndrome or severe pul-
monary hypertension (17%), and unoperated or palliated
complex CHD with functionally single ventricle (14% of
deaths; Table 1). Interestingly, there was no death in the
Fontan group of patients. Low or zero mortality was
found also in coarctation of the aorta, tetralogy of Fallot,
pulmonary stenosis, atrial septal defect type secundum,
congenitally corrected transposition of the great arteries,
ventricular septal defect, and congenital aortic valve
disease (Table 1). The cause of death was cardiovascular
in 97%. Most patients (28; 80%) died from heart failure
either without relation to operation (25 patients) or in the
Table 2
NT-proBNP in the prediction of death
NT-proBNP cut-off (pg/ml) Type of cut-off Samples Sensitivity Speciﬁcity PPV NPV AUC
220 Median of all samples 1242 92 % 53 % 10 % 99 % 0.85
1548 Median of deceased 77 49 % 93 % 36 % 97 %
203 Median of survivors 1165 94 % 51 % 10 % 99 %
630 Maximal sensitivity and speciﬁcity 1242 74 % 84 % 18 % 98 %
AUC ¼ area under curve; NPV ¼ negative predictive value; PPV ¼ positive predictive value.
Table 3
Median values of NT-proBNP in alive and deceased patients with particular
congenital heart diagnoses
Diagnosis Survivors Deceased
NT-proBNP
(pg/ml)
Patients NT-proBNP
(pg/ml)
Patients
Pulmonary atresia 296 22 3264 2
Congenitally corrected
transposition of the
great arteries
211 22 - 0
Ventricular septal defect* 170 34 - 0
Fontan correction† 220 (27) - 0
Single ventricle† incl.
Tricuspid atresia
470 43 1184 5
Eisenmenger syndrome or
severe pulmonary
hypertension*
351 45 2706 6
Coarctation of the aorta 101 25 - 0
Ebstein anomaly of the
tricuspid valve
250 43 304 6
Transposition of the
great arteries
220 77 4352 9
Tetralogy of Fallot 183 94 300 2
Atrial septal defect 206 89 2410 1
Atrio-ventricular septal
defect
195 26 1548 3
Truncus arteriosus 144 3 - 0
Pulmonary stenosis 101 28 1412 1
Congenital aortic
valve disease
118 56 - 0
Other 80 4 - 0
Together 203 611 1548 35
* Patients with ventricular septal defect, atrial septal defect, or any other
lesion with severe pulmonary hypertension are included only in the
Eisenmenger group.
† All patients with Fontan correction are included also in the single
ventricle group.
Figure 1. KaplaneMeier survival curve stratiﬁed according to the cut-off
value of NT-proBNP 630 pg/ml.
Figure 2. The relation between the cut-off values of baseline NT-proBNP
(pg/ml) and the mortality rate in patients with NT-proBNP higher than
each of the cut-off values. 95% conﬁdence intervals are shown in dashed
lines.
Congenital Heart Disease/NT-proBNP in Congenital Heart Disease 1427early postoperative period (3 patients). Other causes of
death were arrhythmia or sudden death (3 patients), he-
moptysis (1 patient), stroke (1 patient), complication of
ventricular assist device (1 patient), and tumor (1
patient).
The median of NT-proBNP was 220 (interquartile range
110 to 474) pg/ml in the whole cohort, 203 (101 to 420) pg/ml
in the group of survivors, and 1,548 (473 to 3,828) pg/ml in
the group of deceased patients (Table 2). The difference
between survivors and deceased patients was highly signiﬁ-
cant (p <0.0001; ManneWhitney U test). The median values
of NT-proBNP in survivors and deceased patients with
particular congenital heart diagnoses are listed in Table 3.The optimal discrimination value of NT-proBNP for the
prediction of death was 630 pg/ml with 74% sensitivity,
84% speciﬁcity, 18% positive predictive value, and 98%
negative predictive value. The optimal discrimination value
was estimated at a value of maximal speciﬁcity and sensi-
tivity. The AUC was 0.85 (Table 2). The long-term survival
rate was 94% in the group with NT-proBNP <630 pg/ml
compared to 65% survival rate in patients with NT-proBNP
630 pg/ml, p <0.0001 (Figure 1).
The use of median of all samples (220 pg/ml) as the
discrimination value for mortality had higher sensitivity
(92%) but lower speciﬁcity (53%). The cutoff 1,548 pg/ml
had high speciﬁcity (93%) but lower sensitivity (49%;
Table 2). There was only 1% mortality (4 patients) in the
Table 4
Maximal and baseline NT-proBNP in the prediction of death
a: Maximal NT-proBNP concentrations
NT-proBNP cut-off (pg/ml) Type of cut-off Patients Sensitivity Speciﬁcity PPV NPV AUC
203 Median of survivors 611 94 % 56% 9.5% 99% 0.87
1974 Median of deceased 35 46 % 96% 27% 97%
220 Median of all patients 646 91 % 58% 10% 99%
b: Baseline NT-proBNP concentrations
NT-proBNP cut-off (pg/ml) Type of cut-off Patients Sensitivity Speciﬁcity PPV NPV AUC
177 Median of survivors 611 94 % 50 % 9 % 99 % 0.85
1099 Median of deceased 35 54 % 92 % 22 % 97 %
183 Median of all patients 646 94 % 50 % 9 % 99 %
AUC ¼ area under curve; Baseline concentrations ¼ the ﬁrst measurement for each patient; Maximal concentrations ¼ the maximal measurement for each
patient; NPV ¼ negative predictive value; PPV ¼ positive predictive value; Type of cutoff ¼ median value of NT-proBNP in the given group of patients.
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220 pg/ml. On the contrary, the mortality rate was as high
as 41% (22 deceased patients) in 54 patients with at least
1 NT-proBNP value >1,548 pg/ml during the follow-up.
The relation between different NT-proBNP cut-off values
and the mortality is shown in Figure 2.
Maximal NT-proBNP was highly predictive of mortality
(AUC 0.87) with signiﬁcantly different survival curves for
cut-off value of 630 pg/ml (p <0.0001; Table 4a). Inter-
estingly, also the baseline NT-proBNP was similarly pre-
dictive (AUC 0.85) with signiﬁcantly different survival
curves for cut-off value of 630 pg/ml (p<0.0001; Table 4b).
We also assessed the hazard associated with baseline
NT-proBNP as a continuous variable after logarithmic
transformation (to reduce the effect of extreme values
because the distribution of NT-proBNP is highly skewed).
Values of baseline log10 NT-proBNP were strongly associ-
ated with the high risk of death (p <0.0001, HR 7, 95%
conﬁdence interval 4 to 13, Cox proportional HR) with the
interpretation that a 10-fold increase in NT-proBNP corre-
sponds to a 7-fold increase in the risk of death. Thus, the
sole baseline measurement of NT-proBNP has the potential
to predict mortality in ACHD.
For the evaluation of the NT-proBNP dynamics, we
compared the ratio of the last and baseline NT-proBNP
value in 295 patients with repeated testing. This ratio was
nonsigniﬁcantly greater in deceased patients (median 1.33
vs 1.08, p ¼ 0.198, ManneWhitney U test).
Discussion
Our results show that the sole NT-proBNP evaluation has
the potential to stratify adult patients with CHD according to
the risk of mortality in long-term follow-up. The best
discrimination was achieved with the cut-off value of 630
pg/ml. There was 94% survival rate in the next 6 years in
patients with NT-proBNP below this limit and only 65%
survival rate in those with the values previously mentioned
(p <0.0001). We did not ﬁnd any prognostic difference
between the baseline and maximal values of NT-proBNP in
the case of repeated testing. It is important to realize that
even a single (baseline) NT-proBNP assessment in a patientin stabilized state without signs of heart failure has the
power to predict the prognosis. All blood samples in this
study were obtained during the planned outpatient visits; the
values of NT-proBNP from hospitalized patients would be
greater.
The serum levels of NT-proBNP in our 646 patients with
ACHD were markedly higher than in general healthy pop-
ulation but also compared with another large ACHD study
with patients of similar age.7,15 The difference might be
explained by that our cohort comprised also patients with
Eisenmenger syndrome, and our whole group was signiﬁ-
cantly more symptomatic (19% in NYHA classes III to IV)
compared with that of Eindhoven’s group with only 1% of
patients in NYHA class III.15
A smaller study with 49 symptomatic patients with CHD
showed that both BNP and atrial natriuretic peptide have
strong predictive value for the mortality in symptomatic
ambulatory patients during long-term follow-up.17 The
mortality rate in this study was higher than that of our study
(22% vs 5%). There was similar rate of symptomatic pa-
tients in functional classes III and IV (20% vs 19%) but
more cyanotic patients compared with our study (20% vs
7%).
Three other studies identiﬁed natriuretic peptides as
predictors of mortality in patients with Eisenmenger syn-
drome or pulmonary hypertension.18e20 The ﬁnding that
elevated levels of BNP >140 pg/ml increase the risk of
death and heart failure in outpatients with Eisenmenger
syndrome is similar to our results.18 In another study, BNP
predicted survival in Eisenmenger syndrome independently
on 6-minute walking distance.19 Also temporal increase of
BNP predicts mortality which corresponds well with our
experience.19 We found that patients with at least 1 level of
NT-proBNP over 1,548 pg/ml (median of deceased patients)
had 41% mortality. Schuuring et al20 has recently observed
that the baseline level of NT-proBNP 500 ng/l was
a signiﬁcant determinant of mortality in patients with
ACHD and pulmonary hypertension, which is very similar
to our results for the whole ACHD cohort.
Natriuretic peptides and their relations to clinical and
echocardiographic parameters have been recently studied in
different particular CHDs.16,18e28 The neurohormonal
Congenital Heart Disease/NT-proBNP in Congenital Heart Disease 1429activation in ACHD may persist many years after repair, and
it was found even in asymptomatic patients.13,29 Residual
lesions after repair may become more important during the
time. From the practical point of view, the ordinary methods
of identifying patients at risk are often problematic in
ACHD. The evaluation of symptoms may be difﬁcult
because most patients with ACHD consider their limited
functional capacity normal. They do not report problems
unless arrhythmia or intercurrent disease with subsequent
heart failure occurs. The result of exercise testing may be
dependent on the regular training. The echocardiographic
evaluation of ejection fraction may be inaccurate in the
abnormal morphology of the ventricles and may be over-
estimated by volume overload of the right or left ventricle.
Nevertheless, it is important to distinguish patients with
high risk in ACHD to provide them with appropriate treat-
ment in time. If we wait too long until substantial symptoms
develop (NYHA classes III to IV), the prognosis is much
worse regardless of the treatment.
In conclusion, our results show that NT-proBNP can be
an extremely useful, quick, and simple prognostic marker
for identiﬁcation of patients at high risk. Although it obvi-
ously cannot replace regular clinical, echocardiographic,
and complex examinations in specialized centers, our results
suggest that it can add very valuable prognostic information.
Early detection of increased mortality risk allows taking
appropriate therapeutic measures in time.
Our study has some limitations: we did not perform
repeated measurements of NT-proBNP in all our patients.
Repeated testing was more likely performed in patients with
more severe disease. We did not compare NT-proBNP with
any other prognostic markers, functional class, echocardio-
graphic parameters, or exercise tests. We did not analyze
early postoperative changes of NT-proBNP after cardiac
surgery for congenital condition in adulthood. On purpose,
we did not analyze NT-proBNP during hospitalization for
heart failure or arrhythmias. The primary end point of our
study was the mortality only; we did not analyze any other
adverse events, worsening of heart failure, or hospital
admissions. The risk stratiﬁcation by NT-proBNP was
performed on purpose for the whole heterogeneous group of
patients with different diagnoses.Acknowledgment: We would like to thank The Bakala
Foundation for ﬁnancial support of Markéta Tomková and
Jakub Tomek during their studies.
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